Skip to main content
. 2021 Nov 18;82(1):36–45. doi: 10.1158/0008-5472.CAN-21-1692

Figure 3.

Figure 3. CRISPR-mediated enrichment of mutations in Trp53 can be inhibited. A, Left, inhibitors used in A and B. Right, WT and Trp53 KO Hox cells (Cas9+ and GFP+) were mixed and transduced with a sgGFP virus in the presence of inhibitors. Cells were then cultured for 7 days, followed by quantification of the frequency of Trp53 mutations by sequencing. B, WT and Trp53 KO B16 cells were mixed and transduced with sgGFP virus in the presence of a selection of inhibitors. Cells were then cultured for 7 days, followed by quantification of the frequency of Trp53 mutations by sequencing. Data are shown as mean and individual values, n = 4 (A and B). Data are combined from two independently experiments performed in two duplicates (A and B). ***, P < 0.001 by one-way ANOVA and Tukey posttest (A and B).

CRISPR-mediated enrichment of mutations in Trp53 can be inhibited. A, Left, inhibitors used in A and B. Right, WT and Trp53 KO Hox cells (Cas9+ and GFP+) were mixed and transduced with a sgGFP virus in the presence of inhibitors. Cells were then cultured for 7 days, followed by quantification of the frequency of Trp53 mutations by sequencing. B, WT and Trp53 KO B16 cells were mixed and transduced with sgGFP virus in the presence of a selection of inhibitors. Cells were then cultured for 7 days, followed by quantification of the frequency of Trp53 mutations by sequencing. Data are shown as mean and individual values, n = 4 (A and B). Data are combined from two independently experiments performed in two duplicates (A and B). ***, P < 0.001 by one-way ANOVA and Tukey posttest (A and B).